Gefitinib, erlotinib and afatinib are three widely used epidermal growth factor receptor
tyrosine kinase inhibitors (EGFR TKIs) for treating advanced non‐small cell lung cancer …

Lung cancer first line treatment has been directed from the non-specific cytotoxic doublet
chemotherapy to the molecular targeted. The major limitation of the targeted therapies still …

Abstract Background. Tyrosine kinase inhibitors (TKIs) targeting the epidermal growth factor
receptor (EGFR) have been evaluated in patients with metastatic and advanced non-small …

Lung cancer is the leading cause of cancer-related death in the world. Prior to the era of
targeted therapy, platinum-based doublet chemotherapy was the first-line therapy of choice …

The present network meta‑analysis aimed to compare the effectiveness and adverse effects
of gefitinib, erlotinib and icotinib in the treatment of patients with non‑small cell lung cancer …

Background The first-generation epidermal growth factor receptor tyrosine kinase inhibitors
gefitinib and erlotinib have both been proven effective for treating advanced non–small cell …

Purpose: The aim of the present study was to develop a simple and rapid reversed-phase
high performance liquid chromatographic method with UV detection for erlotinib …

Background: The epidermal growth factor receptor tyrosine kinase inhibitors gefitinib and
erlotinib are effective for advanced non-small cell lung cancer (NSCLC). This meta-analysis …

目的: 探讨晚期非小细胞肺癌(non-small cell lung cancer, NSCLC) 的基本中医证型. 方法:
纳入晚期NSCLC 患者338 例, 收集患者的临床症状, 应用因子分析方法对症状进行分类 …

Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are an effective
treatment for advanced non-small cell lung cancer. The objective of the present study was to …